Clinical studies in Geriatrics confirm that NAD+levels are directly proportional to the dosage of NMN supplementation
NAD+(nicotinamide adenine dinucleotide) exists in every living cell and is an important biological cofactor. As people age, the level of NAD+in cells gradually decreases, so people hope to increase the level of NAD+by supplementing the precursor NMN (nicotinamide mononucleotide) of NAD+.
A clinical study using the Indian population as a sample confirmed the safety and efficacy of orally supplementing NMN for humans, which was published in GeroScience in December 2022.
In this clinical trial, researchers selected 80 middle-aged individuals aged 40-65 as participants. They were evenly divided into four groups and given daily oral doses of 0, 300, 600, and 900mg of β-nicotinamide mononucleotide. The experiment lasted for a total of 60 days, and researchers observed the changes in NMN supplementation before and after using a series of methods such as blood NAD+level detection and 6-minute walking test.
The results showed that oral β-nicotinamide mononucleotide significantly increased NAD+levels in the blood, but there was no significant difference in the improvement effect between doses of 600mg/day and 900mg/day. And the subjects still had no adverse reactions at a high dose of 900mg.
In addition, subjects who supplemented with NMN performed better in the 6-minute walk test and scored higher in the Self Health Survey Questionnaire (SF-36).
In summary, this experiment has demonstrated that oral supplementation of β-nicotinamide mononucleotide in humans can increase NAD+levels in the blood,
It can also improve the exercise ability of the subjects to a certain extent, which is consistent with previous research results on mice. The subjects who took 900mg/day of NMN orally simultaneously did not experience any adverse reactions, which provides a dose reference for future clinical studies of β-nicotinamide mononucleotide.
GSH Bio-Tech company integrates research, production and sales, focusing on the innovative research and development of high value-added APIs, important pharmaceutical intermediates and cosmetic raw materials.
Reference:
Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45(1), 29–43. https://doi.org/10.1007/s11357-022-00705-1
